|
A.A. Kondrashov, N.A. Shostak
Bone mineral density and androgenic status in men with rheumatoid arthritis
|
№12 / 2021
|
|
E.A. Kulyaev (1), A.V. Grafov (1), O. V. Falameeva (1), V.S. Kholodkin (1), M.A Sadovoy (1, 2), O.V. Tsygankova (2)
EXPERIENCE OF THE USE OF ZOLEDRONIC ACID (REZOLLASTIN 5 MG/6.25 ML, OOO «NATIVA») IN PATIENTS WITH LOW BONE MINERAL DENSITY IN THE SETTINGS OF THE CENTER FOR PREVENTION OF OSTEOPOROSIS OF NOVOSIBIRSK SRITO
|
№19 / 2017
|
|
E.V. Biryukova
MODERN OPPORTUNITIES OF BONE ANABOLIC THERAPY OF OSTEOPOROSIS
|
№5 / 2017
|
|
S.S. Rodionova, U.R. Khakimov
RATIONALE FOR USE OF ALFACALCIDOL IN COMBINATION WITH BISPHOSPHONATES IN POSTMENOPAUSAL AND SENILE FORMS OF SYSTEMIC OSTEOPOROSIS
|
№s3-16 / 2016
|
|
D.V. Stafeev, A.Yu. Kochish, S.N. Ivanov
EVALUATION OF THE EFFICACY OF THERAPY OF OSTEOPOROSIS IN PATIENTS WITH EXTRA-ARTICULAR FRACTURES OF THE PROXIMAL FEMUR
|
№5 / 2016
|
|
I.E. Zhila, O.V. Galkina, E.O. Bogdanova, N.L. Shaporova, O.V. Dudina
OSTEOPOROSIS IN PATIENTS WITH BRONCHO-OBSTRUCTIVE PATHOLOGY
|
№s4-15 / 2015
|
|
O.V. Yakushevskaya
OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
|
№s5-14 / 2014
|
|
D.V. Akimova
RISK FACTORS FOR OSTEOPOROSIS
|
№7 / 2014
|
|
E.V. Biryukova
DO WE KNOW EVERYTHING ABOUT TREATMENT OF STEROID-INDUCED OSTEOPOROSIS?
|
№s5-13 / 2013
|
|
A.F.Verbovoy, L.A.Sharonova, N.I.Verbovaya, D. V. Demidova, A.V.Kapishnikov
The Levels Of Vitamin D3 And Parameters Of Bone Metabolism In Women With Type 2 Diabetes Mellitus
|
№5 / 2013
|
|
L.A.Ruyatkina, A.V.Lomova, D. S. Ruyatkin
Bone Status In Type 2 Diabetes Mellitus
|
№5 / 2013
|
|
M.I. Yarmolinskaya, V.F. Bezhenar
Experience Of Use Of Dienogest In Combined Treatment Of Endometriosis
|
№3 / 2013
|
Русский
